U.S. Markets close in 5 hrs 53 mins

Burning Rock Biotech Limited (BNR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.83-0.53 (-1.43%)
As of 10:03AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close37.37
Open36.72
Bid36.93 x 1000
Ask37.28 x 4000
Day's Range36.72 - 38.05
52 Week Range18.64 - 39.75
Volume37,037
Avg. Volume306,821
Market Cap3.824B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher
    Zacks

    Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher

    Burning Rock (BNR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • MarketWatch

    OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares

    Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd. to bring OncoCyte's DetermaRX test for early-stage lung cancer patients to China. Trading volume spiked to 8.3 million shares, compared with the full-day average of about 419,500 shares. "This agreement with Burning Rock accelerates the ongoing expansion of our DetermaRx test to patients and physicians outside the U.S., and exemplifies our global growth strategy," said OncoCyte Chief Executive Ron Andrews. The news and stock's rally comes as several OncoCyte executives and directors disclosed that they acquired shares on Dec. 11, as "repayment of deferred compensation in lieu of cash at a price of $2.07 per share," which was 2.4% below Monday's closing price. The stock has lost 5.8% year to date through Monday, while the S&P 500 has gained 12.9%.

  • Is BNR A Good Stock To Buy Now?
    Insider Monkey

    Is BNR A Good Stock To Buy Now?

    In this article you are going to find out whether hedge funds think Burning Rock Biotech Limited (NASDAQ:BNR) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus […]